Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 46

1.

Systemic lupus erythematosus and the economic perspective: a systematic literature review and points to consider.

Turchetti G, Yazdany J, Palla I, Yelin E, Mosca M.

Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S116-22. Review.

2.

The humanistic and economic burden of systemic lupus erythematosus : a systematic review.

Meacock R, Dale N, Harrison MJ.

Pharmacoeconomics. 2013 Jan;31(1):49-61. doi: 10.1007/s40273-012-0007-4. Review.

PMID:
23329592
3.

Economic impact of lupus.

Clarke A.

Am J Manag Care. 2001 Oct;7(16 Suppl):S496-501. Review.

4.

The socioeconomic burden of systemic lupus erythematosus: state-of-the-art and prospects.

Zhu TY, Tam LS, Li EK.

Expert Rev Pharmacoecon Outcomes Res. 2012 Feb;12(1):53-69. doi: 10.1586/erp.11.92. Review.

PMID:
22280197
5.

The economic burden of systemic lupus erythematosus.

Panopalis P, Clarke AE, Yelin E.

Best Pract Res Clin Rheumatol. 2012 Oct;26(5):695-704. doi: 10.1016/j.berh.2012.08.006. Review.

PMID:
23218432
6.

The economic burden of systemic lupus erythematosus in Asia: the current state.

Mak A.

Lupus. 2010 Oct;19(12):1442-6. doi: 10.1177/0961203310374308. Review.

PMID:
20947555
7.

A structured literature review of the direct costs of adult systemic lupus erythematosus in the US.

Slawsky KA, Fernandes AW, Fusfeld L, Manzi S, Goss TF.

Arthritis Care Res (Hoboken). 2011 Sep;63(9):1224-32. doi: 10.1002/acr.20502. Review.

8.

Cost-of-illness studies in systemic lupus erythematosus: A systematic review.

Zhu TY, Tam LS, Li EK.

Arthritis Care Res (Hoboken). 2011 May;63(5):751-60. doi: 10.1002/acr.20410. Review. Erratum in: Arthritis Care Res (Hoboken). 2011 Jul;63(7):1074.

9.

Patient-reported outcome measures for systemic lupus erythematosus clinical trials: a review of content validity, face validity and psychometric performance.

Holloway L, Humphrey L, Heron L, Pilling C, Kitchen H, HĂžjbjerre L, Strandberg-Larsen M, Hansen BB.

Health Qual Life Outcomes. 2014 Jul 22;12:116. doi: 10.1186/s12955-014-0116-1. Review.

10.

The socioeconomic burden of SLE.

Lau CS, Mak A.

Nat Rev Rheumatol. 2009 Jul;5(7):400-4. doi: 10.1038/nrrheum.2009.106. Review.

PMID:
19506585
11.

The economic burden of allergic rhinitis: a critical evaluation of the literature.

Reed SD, Lee TA, McCrory DC.

Pharmacoeconomics. 2004;22(6):345-61. Review.

PMID:
15099121
12.

Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.

Plosker GL, Figgitt DP.

Pharmacoeconomics. 2004;22(6):389-411. Review.

PMID:
15099124
13.

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.

Forbes C, Shirran L, Bagnall AM, Duffy S, ter Riet G.

Health Technol Assess. 2001;5(28):1-110. Review.

14.

Cost-Effectiveness and Affordability of Interventions, Policies, and Platforms for the Prevention and Treatment of Mental, Neurological, and Substance Use Disorders.

Levin C, Chisholm D.

In: Patel V, Chisholm D, Dua T, Laxminarayan R, Medina-Mora ME, editors. Mental, Neurological, and Substance Use Disorders: Disease Control Priorities, Third Edition (Volume 4). Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2016 Mar 14. Chapter 12.

15.

Belimumab: review of use in systemic lupus erythematosus.

Boyce EG, Fusco BE.

Clin Ther. 2012 May;34(5):1006-22. doi: 10.1016/j.clinthera.2012.02.028. Review.

PMID:
22464040
16.

Economic burden of urgency urinary incontinence in the United States: a systematic review.

Coyne KS, Wein A, Nicholson S, Kvasz M, Chen CI, Milsom I.

J Manag Care Pharm. 2014 Feb;20(2):130-40. Review.

17.

Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis.

Borba HH, Wiens A, de Souza TT, Correr CJ, Pontarolo R.

BioDrugs. 2014 Apr;28(2):211-28. doi: 10.1007/s40259-013-0074-x. Review.

PMID:
24190520
18.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

20.

A Systematic Review of the Economic and Humanistic Burden of Gout.

Shields GE, Beard SM.

Pharmacoeconomics. 2015 Oct;33(10):1029-47. doi: 10.1007/s40273-015-0288-5. Review.

PMID:
25969152
Items per page

Supplemental Content

Support Center